Zoetis Inc. is a global leader in the animal health industry, dedicated to discovering, developing, manufacturing, and commercializing a broad array of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision animal health solutions. The company draws on a heritage of nearly 75 years to predict, prevent, detect, and treat illness across eight core species groups: dogs, cats, and horses (companion animals) and cattle, swine, poultry, fish, and sheep (livestock). Its product offerings are organized into seven major therapeutic categories: parasiticides, vaccines, dermatology treatments, antiinfectives, pain and sedation agents, other pharmaceuticals, and animal health diagnostics. Zoetis serves veterinarians, pet owners, and livestock producers worldwide, providing solutions that support animal health and productivity from the clinic to the farm.

Zoetis generates revenue principally from the sale of its animal health products to veterinarians, pet owners, and livestock producers across the globe. In 2025, total revenue was divided between the United States segment, which contributed $5,097 million or 54% of sales, and the International segment, which contributed $4,254 million or 45% of sales. Within the United States segment, approximately 83% of revenue came from companion animal products and 17% from livestock products. In the International segment, companion animal products accounted for about 56% of revenue while livestock products made up the remaining 44%. The company also derives a modest share of revenue, roughly 1%, from its Client Supply Services organization that performs contract manufacturing for third parties and from a small line of human health products.

Zoetis holds a leading position in the global animal health market, supported by its extensive product range that spans both companion animals and livestock and covers preventive, therapeutic, and diagnostic solutions. The company’s scale enables substantial investment in research and development, allowing it to bring new medicines and technologies to market at a steady pace. Its geographic footprint, with strong operations in the United States and a diverse international presence across Europe, Asia, Latin America, Africa, and the Middle East, provides a buffer against regional economic fluctuations. Competitive advantages include a balanced portfolio across species and product categories, deep relationships with veterinarians and producers, and a reputation for innovation and quality.

The company’s customers include veterinarians who depend on its medicines, vaccines, and diagnostics to care for companion and food animals. Pet owners purchase Zoetis products to prevent illness and treat conditions in dogs, cats, and horses. Livestock producers use the company’s solutions to protect herd health, enhance growth rates, and support safe food production.